June 2026
Create an account to continue using Similarweb
View website metrics, keywords, top marketing channels, market research tools, and more.
Create your free accountcancerscan.jp
Global Rank
#3,200,572
500,855Showing Similarweb estimated data.
Publicly validate your site’s metrics by connecting your GA4
Reflect your success
Verify your website's traffic and engagement metrics by connecting to Google Analytics
Bounce Rate
37.87%
Pages per Visit
5.10
Avg Visit Duration
00:01:39
Top 10 cancerscan.jp Competitors
The Top 10 Sites Like cancerscan.jp in June 2026 are ranked by their affinity to cancerscan.jp in terms of keyword traffic, audience targeting, and market overlap
富士山の標高1000m地点、地下273メートルより採水したバナジウム(85マイクログラム)入りの天然水を製造から宅配まで一貫したサービスで、ウォーターサーバーを使用した1wayモデルのhod形式にて、お届けします。最高品質の天然水をぜひお召し上がりください。
Global Rank
#8,185,353
2,091,203Bounce Rate
39.32%
Pages per Visit
2.38
Avg Visit Duration
00:00:24
Similarity Score
100%株式会社ウィルゲート(本社:東京都渋谷区、代表取締役:小島 梨揮、以下 ウィルゲート)が提供するSEO分析ツー
Global Rank
#1,108,394
198,630Bounce Rate
70.52%
Pages per Visit
1.61
Avg Visit Duration
00:01:22
Similarity Score
100%LINEを使って簡単お問い合わせ!So-netアカウントと友だちになるだけで「モモ」とオペレーターがいつでも対応。
- Company
- - -
- Industry
- - -
Global Rank
- -
Country Rank
- -
Category Rank
- -
Bounce Rate
24.18%
Pages per Visit
11.41
Avg Visit Duration
00:17:12
Similarity Score
52%複十字シール運動 複十字シール運動は、結核をなくし、健康で明るい社会実現のために世界各地で行われている運動です。
- Company
- - -
- Industry
- - -
Global Rank
#2,490,546
403,553Bounce Rate
48.91%
Pages per Visit
2.26
Avg Visit Duration
00:01:24
Similarity Score
28%cancerscan.jp's top 5 competitors in June 2026 are: fuji-meisui.co.jp, willgate.co.jp, secap.so-net.ne.jp, eghca.or.jp, and more.
According to Similarweb data of monthly visits, cancerscan.jp’s top competitor in June 2026 is fuji-meisui.co.jp. cancerscan.jp 2nd most similar site is willgate.co.jp, and closing off the top 3 is secap.so-net.ne.jp.
eghca.or.jp ranks as the 4th most similar website to cancerscan.jp and ranks fifth in June 2026.
The other five competitors in the top 10 list are , , , , and .